SCM
ANIP icon

Soleus Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Soleus Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.8M Buy
867,760
+47,517
+6% +$3.81M 2.48% 9
2026
Q1 		$63.1M Buy
820,243
+334,000
+69% +$26.1M 2.55% 10
2025
Q4 		$38.4M Buy
486,243
+146,000
+43% +$12.6M 1.42% 19
2025
Q3 		$31.2M Buy
340,243
+289,500
+571% +$23.6M 1.57% 20
2025
Q2 		$3.31M Sell
50,743
-173,941
-77% -$11.3M 0.22% 66
2025
Q1 		$15M Buy
224,684
+19,390
+9% +$1.16M 1.08% 27
2024
Q4 		$11.3M Sell
205,294
-63,706
-24% -$3.66M 0.71% 36
2024
Q3 		$16M Buy
+269,000
New +$16.4M 1.24% 30

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Soleus Capital Management's ANIP Position: Q2 2026 in Review

Soleus Capital Management increased its ANI Pharmaceuticals (ANIP) stake by 5.8% in Q2 2026, buying an estimated $3.81M and bringing the position to 867,760 shares worth $71.8M. The position accounts for 2.48% of the portfolio, ranked #9.

Soleus Capital Management first reported a position in ANIP in Q3 2024 and has held it in 8 quarters since. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Soleus Capital Management held 867,760 shares of ANI Pharmaceuticals worth $71.8M as of Q2 2026.
  • Soleus Capital Management bought 47,517 ANI Pharmaceuticals shares in Q2 2026, an estimated $3.81M.
  • ANI Pharmaceuticals made up 2.48% of Soleus Capital Management's portfolio in Q2 2026, its #9 holding.
  • Soleus Capital Management first reported a position in ANI Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.